Syntara Earns $1.7M as Parkinson’s Trial Treats Final Patient and Eyes 2026 Data
Syntara Limited is a clinical-stage drug development company dedicated to bringing innovative and life-changing treatments to patients with unmet medical needs. The company specializes in targeting extracellular matrix (ECM) dysfunction through its world-leading expertise in amine oxidase chemistry, focusing on developing novel medicines for blood cancers, inflammatory conditions, and fibrotic diseases.
The company’s primary research is concentrated on correcting ECM dysfunction by developing effective inhibitors of key enzymes involved in various disease states. Their clinical pipeline includes promising treatments for haematological malignancies such as myelofibrosis and myelodysplastic syndrome, as well as research into skin fibrosis, neuroinflammatory diseases, and other chronic conditions like pulmonary fibrosis, MASH, and cardiac fibrosis. Their lead candidate, amsulostat, is currently undergoing a Phase 2 multinational study targeting myelofibrosis.
Syntara’s approach is grounded in a deep understanding of oxidase enzyme chemistry and biology, which allows them to develop targeted therapies for chronic diseases with high unmet medical needs. The company is actively conducting clinical trials across multiple therapeutic areas, including a collaboration with Parkinson’s UK, demonstrating their commitment to advancing medical treatments that can potentially improve patient outcomes and quality of life.
Join +20,000 subscribers receiving alerts.
Join thousands of investors who rely on StockWire X for timely, accurate market intelligence.
StockWire X delivers fast, reliable, and actionable insights into significant developments across global markets, with coverage spanning technology, biotechnology, healthcare, financials, and emerging industries. Our mission is to provide clear, data-driven content that empowers investors to identify opportunities and make informed decisions ahead of the market.
Our network spans key financial and investment hubs worldwide, ensuring subscribers receive timely updates on market-moving announcements, news, macroeconomic trends, and corporate developments.
Use of Technology
We harness advanced technologies to enhance the speed, accuracy, and relevance of our reporting.
While technology accelerates our workflow, every piece of content is selected, validated, and published by human professionals, in accordance with best practices for accuracy, transparency, and investor value. This hybrid approach ensures speed without compromising editorial integrity.
Feedback and Accuracy
We are committed to accuracy and fairness in our reporting. If you believe any information we have published is inaccurate, incomplete, or misleading, please contact us at admin@stockwirex.com so we can review and address the matter promptly.
StockWire X provides readers with access to market news, educational content, and commentary from financial services professionals, industry experts, and companies (“Contributors”).
StockWire X does not hold an Australian Financial Services Licence (AFSL) and relies on the exemption available under section 911A(2)(eb) of the Corporations Act 2001 (Cth) in respect of any financial product advice provided.
Any advice or information published by StockWire X is general in nature only and has been prepared without taking into account your personal objectives, financial situation, or needs. Before acting on any information, you should consider whether it is appropriate for your circumstances and seek independent, licensed financial advice. You should also obtain and read any relevant Product Disclosure Statement (PDS) or other offer document before making an investment decision.
StockWire X makes no guarantee as to the accuracy, completeness, or timeliness of the information provided, and accepts no responsibility for any loss arising from reliance on it. All content is published in good faith for informational purposes only.
StockWire X may have commercial relationships with some contributors or companies mentioned in our content. Any such relationships will be disclosed where relevant.
If you believe any information we have published is inaccurate, incomplete, or misleading, please contact us at admin@stockwirex.com so we can review and address the matter promptly.
